167 related articles for article (PubMed ID: 37925934)
21. Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer.
Schuler KM; Rambally BS; DiFurio MJ; Sampey BP; Gehrig PA; Makowski L; Bae-Jump VL
Cancer Med; 2015 Feb; 4(2):161-73. PubMed ID: 25417601
[TBL] [Abstract][Full Text] [Related]
22. A review for clinicians: Prostate cancer and the antineoplastic properties of metformin.
Hankinson SJ; Fam M; Patel NN
Urol Oncol; 2017 Jan; 35(1):21-29. PubMed ID: 27836248
[TBL] [Abstract][Full Text] [Related]
23. Metformin attenuates transforming growth factor beta (TGF-β) mediated oncogenesis in mesenchymal stem-like/claudin-low triple negative breast cancer.
Wahdan-Alaswad R; Harrell JC; Fan Z; Edgerton SM; Liu B; Thor AD
Cell Cycle; 2016; 15(8):1046-59. PubMed ID: 26919310
[TBL] [Abstract][Full Text] [Related]
24. TGF-β1 stimulates migration of type II endometrial cancer cells by down-regulating PTEN via activation of SMAD and ERK1/2 signaling pathways.
Xiong S; Cheng JC; Klausen C; Zhao J; Leung PC
Oncotarget; 2016 Sep; 7(38):61262-61272. PubMed ID: 27542208
[TBL] [Abstract][Full Text] [Related]
25. Metformin prevents BAFF activation of Erk1/2 from B-cell proliferation and survival by impeding mTOR-PTEN/Akt signaling pathway.
Chen X; Ma J; Yao Y; Zhu J; Zhou Z; Zhao R; Dong X; Gao W; Zhang S; Huang S; Chen L
Int Immunopharmacol; 2021 Jul; 96():107771. PubMed ID: 34004440
[TBL] [Abstract][Full Text] [Related]
26. A Smad3-PTEN regulatory loop controls proliferation and apoptotic responses to TGF-β in mouse endometrium.
Eritja N; Felip I; Dosil MA; Vigezzi L; Mirantes C; Yeramian A; Navaridas R; Santacana M; Llobet-Navas D; Yoshimura A; Nomura M; Encinas M; Matias-Guiu X; Dolcet X
Cell Death Differ; 2017 Aug; 24(8):1443-1458. PubMed ID: 28524854
[TBL] [Abstract][Full Text] [Related]
27. Palbociclib has antitumour effects on Pten-deficient endometrial neoplasias.
Dosil MA; Mirantes C; Eritja N; Felip I; Navaridas R; Gatius S; Santacana M; Colàs E; Moiola C; Schoenenberger JA; Encinas M; Garí E; Matias-Guiu X; Dolcet X
J Pathol; 2017 Jun; 242(2):152-164. PubMed ID: 28349562
[TBL] [Abstract][Full Text] [Related]
28. Metformin suppresses cancer cell growth in endometrial carcinoma by inhibiting PD-L1.
Xue J; Li L; Li N; Li F; Qin X; Li T; Liu M
Eur J Pharmacol; 2019 Sep; 859():172541. PubMed ID: 31319067
[TBL] [Abstract][Full Text] [Related]
29. Effects of metformin and phenformin on apoptosis and epithelial-mesenchymal transition in chemoresistant rectal cancer.
Park JH; Kim YH; Park EH; Lee SJ; Kim H; Kim A; Lee SB; Shim S; Jang H; Myung JK; Park S; Lee SJ; Kim MJ
Cancer Sci; 2019 Sep; 110(9):2834-2845. PubMed ID: 31278880
[TBL] [Abstract][Full Text] [Related]
30. Metformin attenuates the epithelial-mesenchymal transition of lens epithelial cells through the AMPK/TGF-β/Smad2/3 signalling pathway.
Wang L; Tian Y; Shang Z; Zhang B; Hua X; Yuan X
Exp Eye Res; 2021 Nov; 212():108763. PubMed ID: 34517004
[TBL] [Abstract][Full Text] [Related]
31. Metformin modulate immune fitness in hepatocellular carcinoma: Molecular and cellular approach.
Abd El-Fattah EE; Zakaria AY
Int Immunopharmacol; 2022 Aug; 109():108889. PubMed ID: 35679661
[TBL] [Abstract][Full Text] [Related]
32. Hyaluronic acid engrafted metformin loaded graphene oxide nanoparticle as CD44 targeted anti-cancer therapy for triple negative breast cancer.
Basu A; Upadhyay P; Ghosh A; Bose A; Gupta P; Chattopadhyay S; Chattopadhyay D; Adhikary A
Biochim Biophys Acta Gen Subj; 2021 Mar; 1865(3):129841. PubMed ID: 33412224
[TBL] [Abstract][Full Text] [Related]
33. MiRNA-21 mediates the antiangiogenic activity of metformin through targeting PTEN and SMAD7 expression and PI3K/AKT pathway.
Luo M; Tan X; Mu L; Luo Y; Li R; Deng X; Chen N; Ren M; Li Y; Wang L; Wu J; Wan Q
Sci Rep; 2017 Feb; 7():43427. PubMed ID: 28230206
[TBL] [Abstract][Full Text] [Related]
34. Pharmacophore mapping approach to find anti-cancer phytochemicals with metformin-like activities against transforming growth factor (TGF)-beta receptor I kinase: An in silico study.
Reza R; Morshed N; Samdani MN; Reza MS
PLoS One; 2023; 18(11):e0288208. PubMed ID: 37943796
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of Epithelial-mesenchymal Transition in Response to Treatment with Metformin and Y27632 in Breast Cancer Cell Lines.
Leonel C; Ferreira LC; Borin TF; Moschetta MG; Freitas GS; Haddad MR; de Camargos Pinto Robles JA; Aparecida Pires de Campos Zuccari D
Anticancer Agents Med Chem; 2017; 17(8):1113-1125. PubMed ID: 28042775
[TBL] [Abstract][Full Text] [Related]
36. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
Bian X; Gao J; Luo F; Rui C; Zheng T; Wang D; Wang Y; Roberts TM; Liu P; Zhao JJ; Cheng H
Oncogene; 2018 Jan; 37(3):341-351. PubMed ID: 28945226
[TBL] [Abstract][Full Text] [Related]
37. Metformin Inhibits TGF-β1-Induced Epithelial-to-Mesenchymal Transition via PKM2 Relative-mTOR/p70s6k Signaling Pathway in Cervical Carcinoma Cells.
Cheng K; Hao M
Int J Mol Sci; 2016 Nov; 17(12):. PubMed ID: 27916907
[TBL] [Abstract][Full Text] [Related]
38. MFGE8 regulates TGF-β-induced epithelial mesenchymal transition in endometrial epithelial cells in vitro.
Yu L; Hu R; Sullivan C; Swanson RJ; Oehninger S; Sun YP; Bocca S
Reproduction; 2016 Sep; 152(3):225-33. PubMed ID: 27340235
[TBL] [Abstract][Full Text] [Related]
39. Direct effects of metformin in the endometrium: a hypothetical mechanism for the treatment of women with PCOS and endometrial carcinoma.
Shao R; Li X; Feng Y; Lin JF; Billig H
J Exp Clin Cancer Res; 2014 May; 33(1):41. PubMed ID: 24887156
[TBL] [Abstract][Full Text] [Related]
40. Metformin against TGFβ-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis.
Cufí S; Vazquez-Martin A; Oliveras-Ferraros C; Martin-Castillo B; Joven J; Menendez JA
Cell Cycle; 2010 Nov; 9(22):4461-8. PubMed ID: 21088486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
